Skip to main
NVCR
NVCR logo

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd is positioned for significant revenue growth, driven by a study that may enable Glioblastoma patients to commence treatment 2-3 months earlier, potentially increasing revenue per patient by 20-30%. The company's expansion efforts in the United States and Germany are expected to lead to an increase in active patients throughout 2026, which serves as a critical indicator for future revenue growth trajectories. Additionally, new market entries are anticipated to start generating incremental revenue within the next 12-18 months, complementing existing patient and revenue growth drivers.

Bears say

NovoCure Ltd faces a challenging financial outlook, as a significant drop in EBITDA is anticipated due to slow revenue growth projected over the coming quarters. The expectation is that it may take until 2027 for EBITDA to reach breakeven levels, indicating prolonged financial strain. Given the reliance on revenue ramp-up and the uncertainty associated with achieving these milestones, the outlook for the company's financial performance remains negative.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.